Skip to content
Medical Health Aged Care

Kao Corporation: Regarding the Nomination of Director Candidates for Our Company

Kao Corporation < 1 mins read
TOKYO--BUSINESS WIRE--

Kao's Board of Directors and management team strive to increase shareholder value from a long-term perspective based on our business strategy. For the purpose of enhancing our corporate value, we are committed to engaging directly and constructively with all our stakeholders and welcome new perspectives to address challenges.

Kao adheres to a robust selection process to ensure an optimal composition of the Board of Directors. As announced in the December 12 press release, this fiscal year, the selection of candidates was deliberated over a period of more than six months by the Board of Directors and the Committee for Examination of Nominees for Directors and Audit & Supervisory Board Members. The candidates for Directors and Audit & Supervisory Board Members were announced on December 2 to coincide with the announcement of the new Executive Officer structure.

The announced individuals are proposed candidates and do not preclude proposals from other shareholders. Following our company's selection process, we are currently conducting the appropriate evaluation for the director candidates proposed by certain shareholders.

Kao will remain committed to ensuring fair disclosure of information to all stakeholders.


Contact details:

Media inquiries should be directed to:
Public Relations
Kao Corporation
[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 29/04/2025
  • 00:10
Olon SpA

Olon Group Strengthens Its Leadership in Bioproduction with Two Strategic Appointments in France

MILAN, April 28, 2025 (GLOBE NEWSWIRE) -- Olon Group, a leading global pharmaceutical CDMO, announces the appointment of Jérôme Bédier as CEO of its French entities and Andrea Conforto as M&S VP CDMO of Olon Biotech, the division dedicated to CDMO services for biologics. These appointments reinforce Olon's strategy to expand its capabilities in Antibody-Drug Conjugates (ADCs), Highly Potent Active Pharmaceutical Ingredients (HPAPIs), and microbial bioproduction.An Integrated Vision for ADCs, HPAPIs, and Microbial BioproductionWith this new leadership structure, Olon Group is accelerating the development of its fully integrated ADC offering, covering the entire value chain from Cell Line Development (CLD) to…

  • Medical Health Aged Care
  • 28/04/2025
  • 22:41
Mainstay Medical Holdings plc

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

DUBLIN--BUSINESS WIRE-- Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. The coverage went into effect on April 16, 2025, and expands access to the procedure, when clinically appropriate, to Anthem’s policyholders. “We have been on a 17-year mission to prove the value of ReActiv8 through careful and thorough research,”said Jason Hannon, CEO of Mainstay Medical.“We have…

  • Medical Health Aged Care
  • 28/04/2025
  • 21:26
Eurosets

Life-saving Technologies at EuroELSO 2025: Eurosets Presents Landing Breathe and Xtreme Rescue

MILAN–BUSINESS WIRE– Eurosets, a cutting-edge Italian company specializing in the design of life-saving medical devices, unveils two crucial innovations at the EuroELSO 2025 congress:…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.